A Double-Blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed II Pump.
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2014
At a glance
- Drugs SNN 0029 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- 18 May 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 18 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Jan 2011 Planned end date changed from Mar 2010 to May 2011 as reported by ClinicalTrials.gov.